Been looking into weight loss treatments? You've probably come across Wegovy semaglutide tablets, the oral version of the semaglutide found in Wegovy injections.
The questions most people want answered straight away are how much weight the tablets can help you lose, and how they compare with the injection.
This guide covers what the clinical evidence shows, how the tablet compares with the Wegovy injection, what affects individual results and what a realistic timeline looks like. Wegovy semaglutide tablets (oral semaglutide 25mg) were approved by the MHRA on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management.
Trial averages describe a group, not you. Your own result depends on your dose, your routine and your habits.
How does oral semaglutide cause weight loss?
The Wegovy injection and Wegovy semaglutide tablets contain the same active ingredient: semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
GLP-1 is a hormone your body naturally releases after you eat. Semaglutide mimics it, binding to GLP-1 receptors in your brain and digestive system. That reduces your appetite, slows how quickly your stomach empties and makes you feel fuller after meals.
In practice, most people find it much easier to eat less, without the constant hunger that makes calorie-restricted diets so hard to stick to.
Semaglutide doesn't burn fat directly or speed up your metabolism. The weight you lose comes from eating fewer calories.
The tablet reaches your bloodstream differently from the injection. Semaglutide is a peptide, and stomach acid would normally break it down before it could be absorbed.
To stop this, every Wegovy tablet contains an absorption enhancer called SNAC (salcaprozate sodium). It temporarily protects semaglutide from stomach acid and opens a pathway through your stomach lining.
That's why you take Wegovy tablets on an empty stomach, with a small amount of plain water (up to 120ml, about 4 ounces), and have nothing else for 30 minutes afterwards. Food, other drinks and other oral medicines get in the way of SNAC and significantly reduce how much semaglutide reaches your bloodstream. The prescribing information also notes that absorption is better with smaller amounts of water, so stick to the limit rather than a full glass.
Semaglutide makes eating less easier, but it doesn't do the work for you. Your food choices still matter.
What did the OASIS 4 trial find?
The evidence for Wegovy semaglutide tablets comes mainly from the phase 3 OASIS 4 trial, published in the New England Journal of Medicine in September 2025.
The trial involved 307 adults without diabetes who had a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health problem. They were randomly given either oral semaglutide 25mg once a day or a placebo, alongside lifestyle support, including diet and activity advice, for 64 weeks.1
The results depend on which measure you look at:
- If people stuck with treatment - those taking oral semaglutide lost an average of 16.6% of their body weight by week 64, compared with 2.7% on placebo.1
- Including everyone, whether or not they stuck with it - the average was 13.6%, compared with 2.2% on placebo.1
The difference matters. The 16.6% figure shows what the medicine can do when it's taken consistently and correctly. The 13.6% figure is closer to real life, because it includes people who lowered their dose, paused treatment or stopped altogether.
Both are a meaningful effect compared with placebo.
Looking at milestones among people who stuck with treatment, around 34% lost 20% or more of their body weight, compared with around 3% on placebo. More people on semaglutide also got their blood pressure, blood sugar and cholesterol back into a healthy range by the end of the trial.
How do Wegovy semaglutide tablets compare to the injection?
The Wegovy injection (semaglutide 2.4mg weekly) has its own evidence from the STEP trials. STEP 1 involved 1,961 adults without diabetes, and found average weight loss of 14.9% over 68 weeks on the 2.4mg weekly injection, compared with 2.4% on placebo.2
Putting the OASIS 4 and STEP 1 figures side by side gives a reasonable comparison, though the trials weren't designed to test one against the other.
The tablet's "everyone included" result (13.6%) is slightly below the STEP 1 injection figure (14.9%). The tablet's "stuck with treatment" figure (16.6%) is higher, but that reflects differences in how the two trials measured it, not that the tablet works better.
An indirect comparison presented at ObesityWeek 2025 found that oral and injected semaglutide gave similar weight loss and other health results, once the differences between the trial groups were accounted for.3 Similar proportions of people in each trial lost 5%, 10%, 15% and 20% or more of their body weight.
The practical takeaway? The tablet and the injection are in the same league for weight loss. Less than 1% of each tablet dose reaches your bloodstream, so the tablet needs a much bigger dose to get there.
But the results are close enough that your choice is more likely to come down to convenience and personal preference than how well each one works.
For context, Mounjaro (tirzepatide), which acts on both GLP-1 and GIP receptors, led to greater average weight loss in its main trial: 20.9% over 72 weeks at the highest dose in SURMOUNT-1.4
Tablet or injection, the results are in the same range. Pick the one that fits your life best.
How much weight can you lose in practice?
Clinical trial averages describe a group of people, not you. The range of results in OASIS 4 was wide. Some people lost much more than the average, and some lost less.
A few things affect how well oral semaglutide works for you:
- Following the dosing rules - because absorption depends on SNAC, taking the tablet with food or drink significantly reduces how much semaglutide gets into your bloodstream. Taking it on an empty stomach every time is one of the things you have most control over.
- Completing the dose increases - Wegovy tablets are started at 1.5mg and increased to 25mg over several months, going up every 30 days. People who stop increasing, or lower their dose because of side effects, tend to lose less weight on average than those who reach and stay on 25mg.
- Diet and activity - everyone in OASIS 4 had lifestyle support alongside the medicine. Semaglutide is licensed alongside a reduced-calorie diet and more physical activity, not as a stand-alone treatment. It makes eating less easier, but it doesn't replace the need to do it.
- Whether you have diabetes - people without type 2 diabetes consistently lose more weight on semaglutide than those with it. Everyone in OASIS 4 was non-diabetic, so the 13.6 to 16.6% figures apply to that group specifically.1
- Sex - across several semaglutide trials, women have on average lost a slightly bigger percentage of their weight than men, though the medicine works for both.5
Do not take your tablet with breakfast or coffee. Even a small meal can cut how much medicine you absorb.
How long does it take to see results?
In OASIS 4, weight loss started within the first few weeks of treatment and carried on steadily through the dose increases. Following the dosing schedule, you reach the 25mg maintenance dose at day 91, around the start of your fourth month.
Weight loss often picks up once you're on the full dose, and continued through the 64 weeks of the trial.
Early on, the effect is subtler: a noticeable drop in appetite, and feeling full sooner after smaller meals. The weight change follows from those shifts in how you eat, rather than any direct effect on fat.
Track more than the scales. Waist size, how your clothes fit and your energy levels are early signs it's working.
Who are Wegovy semaglutide tablets suitable for?
The MHRA approved Wegovy semaglutide tablets on 11 June 2026. The UK licence covers adults with obesity (BMI of 30 or above), or overweight (BMI of 27 to 30) with at least one weight-related health condition.
Wegovy tablets aren't suitable if you've had a serious allergic reaction to semaglutide, and they aren't recommended during pregnancy or breastfeeding. Tell your prescriber if you or a family member has had a rare thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia type 2, so they can take it into account.
Have type 2 diabetes? Discuss with your prescriber whether the tablet or injection is the better fit. The prescribing information notes that semaglutide levels from the tablet are lower in people with type 2 diabetes, which may mean a smaller response than with the injection.
To check your eligibility and the latest availability, visit the Wegovy oral tablet page.
Have type 2 diabetes and take insulin or a sulfonylurea? Your prescriber may need to adjust them to avoid low blood sugar.
When to seek further advice
Speak to your GP or prescribing clinician if you:
- Are not seeing any weight reduction after completing dose escalation to 25mg
- Experience persistent or severe nausea, vomiting, or abdominal pain
- Develop symptoms that could indicate pancreatitis: persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. Discontinue the medication and seek medical attention without delay.
- Have concerns about how other medications you take may interact with oral semaglutide, as the tablet's delay of gastric emptying can affect the absorption of other oral medicines
- Are considering starting treatment for the first time and want to discuss whether the tablet or injection would be more appropriate for your situation
Frequently asked questions
Is the Wegovy pill as effective as the injection?
Clinical trial data shows they are closely comparable. In the OASIS-4 trial, Wegovy semaglutide tablets produced an average of 13.6% body weight loss over 64 weeks (based on
all participants regardless of adherence), rising to 16.6% among those who took the full
dose consistently. The Wegovy injection (2.4mg weekly) produced an average of 14.9% over
68 weeks in the STEP 1 trial. An indirect comparison of both trials found similar
proportions of participants achieving 5%, 10%, 15%, and 20% or more body weight reduction.
The tablet is a meaningful alternative for people who prefer not to use injections, with
weight outcomes in the same clinical range.
Do Wegovy semaglutide tablets work for weight loss?
Yes. Wegovy semaglutide tablets (oral semaglutide 25mg) are a licensed treatment for
weight management in adults, backed by the phase 3 OASIS-4 trial published in the New
England Journal of Medicine. Participants taking the tablet alongside diet and activity
support lost an average of 13.6-16.6% of their body weight over 64 weeks, compared with
around 2% in the placebo group. As with any weight loss medicine, results are greater when
combined with a reduced-calorie diet and increased physical activity.
How long does it take for Wegovy semaglutide tablets to work?
Weight loss with Wegovy semaglutide tablets begins within the first few weeks of
treatment, but the full effect builds gradually over several months. The dose escalates
every 30 days, starting at 1.5mg and reaching the maintenance dose of 25mg at day 91 of
treatment. Most of the total weight reduction seen in clinical trials had occurred by week
64. Results are typically most noticeable once you reach and have been on the full 25mg
maintenance dose, which is when the medication is working at its intended level.
Is Wegovy a pill or an injection?
Wegovy is now available in both forms. The Wegovy injection (semaglutide 2.4mg) is
administered once weekly using a prefilled pen, while Wegovy semaglutide tablets (oral semaglutide 25mg) are taken once daily. Wegovy tablets were approved by the MHRA on 11 June 2026 and are expected to be available by private prescription within weeks. Both forms contain the same active ingredient and work through the same mechanism.
Do Wegovy semaglutide tablets affect the contraceptive pill?
Wegovy semaglutide tablets slow gastric emptying, which can affect how quickly other
oral medications pass through the stomach and are absorbed. In a drug interaction study,
the absorption of levothyroxine was increased when taken alongside Wegovy semaglutide tablets.
No clinically significant interaction was found with ethinyl estradiol or levonorgestrel,
the hormones used in most combined oral contraceptives. However, because the tablet can
affect the absorption of some oral medicines, you should tell your prescribing clinician
about all medications you are taking, including contraceptives, before starting treatment.
What percentage of body weight can you lose on Wegovy semaglutide tablets?
In the OASIS-4 trial, participants who took the full 25mg maintenance dose consistently
lost an average of 16.6% of their starting body weight over 64 weeks. Among those
participants, around one in three achieved 20% or more body weight reduction. For all
participants in the trial, including those who reduced or stopped their dose, the average
was 13.6%. Individual outcomes vary depending on adherence to dosing rules, diet and
physical activity, and other personal factors.
References
- Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Novo Nordisk. OASIS 4 indirect comparison: oral and injectable semaglutide comparable outcomes in weight reduction and cardiometabolic measures. Presented at ObesityWeek 2025, Atlanta, November 4-7, 2025.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Strathe AV, Fors JJ, Frandsen CS, et al. A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes, Obesity and Metabolism. 2023;25(9):2487-2496. doi:10.1111/dom.15211
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.